The content on this site is intended for healthcare professionals only
Prof Drew Pardoll talks to ecancer at the 2013 WIN Symposium in Paris about the recent developments in treating cancer with immunotherapy.
Immunotherapy for cancer aims to empower the immune system's antibodies and T-Cells to attack tumours. This occurs through the blockade of regulatory pathways, immune checkpoints, and the reactivation of T-Cells.
The most recent breakthrough in this field has been the results in blocking PD-1 with ipilimumab.
Filmed in Partnership with the WIN Consortium
TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Highlights and analysis
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Assessment of suicide risk in cancer patients
EAU 2024: Bladder cancer latest
mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity
Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence
